EUROPEAN PATENT SPECIFICATION

Date of publication of patent specification: 11.01.95
Int. Cl.⁹: C07D 281/10, A61K 31/55
Application number: 92309474.2
Date of filing: 16.10.92
Divisional application 94201425.9 filed on 16/10/92.
The file contains technical information submitted after the application was filed and not included in this specification.

5-piperazinylalkyl-1,5-benzothiazepinones useful as calcium antagonists.

Priority: 21.10.91 JP 302348/91
Date of publication of application: 12.05.93 Bulletin 93/19
Publication of the grant of the patent: 11.01.95 Bulletin 95/02
Designated Contracting States: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

References cited:
EP-A- 0 394 101
EP-A- 0 429 060
EP-A- 0 433 683
US-A- 4 584 131

Inventor: Yamamori, Teruo
1-8-39, Hikarigaoka
Takarazuka-shi,
Hyogo-ken (JP)
Inventor: Harada, Hiroshi
1-20-16, Midorigaoka
Toyonaka-shi,
Osaka-fu (JP)
Inventor: Sakai, Katsunori
1-4-16, Kaminishi,
Hirano-ku
Osaka-shi,
Osaka-fu (JP)
Inventor: Iwaki, Kazumi
331 Sinkita
Higashiosaka-shi,
Osaka-fu (JP)
Inventor: Matsunaga, Kazuki
6-B-706 Satsukigaoka-higashi
Suita-shi,
Osaka-fu (JP)

Proprietor: SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD.
1-8, Doshomachi 3-chome,
Chuo-ku
Osaka 541 (JP)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).
Description

The present invention relates to novel benzothiazepine derivatives. In more particular, the invention relates to 5-(piperidinylalkyl or piperazinylalkyl)benzothiazepine derivatives useful as Ca-antagonist as well as coronary vasodilator.

USP 3,562,257 discloses benzothiazepine derivatives useful as coronary vasodilator. Although other benzothiazepine derivatives, such as dilthiazem derivatives, are disclosed in USP 4,584,131 and Japanese Patent Publication (not-examined) No. 292271/1989, a particular group of benzothiazepine derivatives, i.e., 5-(piperidinylalkyl or piperazinylalkyl)benzothiazepines of the present invention, which are useful as coronary vasodilator and also Ca-antagonist, i.e., cardiac muscle-protector, have not been reported.

EP-A-0 433 683 discloses certain benzothiazepine derivatives defined by general formula I, wherein the benzothiazepinone is N-substituted by a piperidinoethyl or piperidinopropyl group thereof, and their use for preparing a pharmaceutical composition for treating cancer by potentiating an anti-cancer drug effect in a subject.

Also, EP-A-0 429 060 discloses benzothiazepine derivatives defined by formula I thereof wherein the benzothiazepine is N-substituted by a piperidinoethyl and their use as i.a. vasodilators.

It is well known that contraction of cardiac muscle or vascular smooth muscle is associated with Ca-penetration into cells. Thus, the administration of Ca-antagonist to patients results in suppression of cardiac contraction and coronary vasodilation, and therefore, Ca-antagonist is useful as a therapeutic agent for cardiac diseases such as angina pectoris, cardiac infarction, and arrhythmia, hypertension, and cerebrovascular contracture. Dilthiazem is extensively used for treatment of angina pectoris and essential hypertension, but has a drawback that suppression of cardiac contraction caused by dilthiazem is too drastic. Accordingly, a new medicine free from such drawback has long been desired.

The present inventors have found that a benzothiazepine derivative of the formula (I):

\[
\begin{align*}
\text{Y} & \text{N} \bigg(\text{CH}_2\bigg)_n \text{X} \\
\text{OCH}_3 & \text{Z}
\end{align*}
\]

wherein \( x = N-R' \); \( R' \) is methoxyphenyl; \( Y \) is halogen, methyl or methoxy; \( Z \) is hydrogen or acetyl; \( n \) is an integer of from 3 to 6, and a pharmaceutically acceptable salt thereof shows excellent vasodilating action on extracted blood vessel and strong protecting action on ischemic cardiac muscle when cultured cardiac cells are used. The inventors have also found that the compound of the formula (I) shows only a slight suppressing action on cardiac functions, and that a compound of the invention is useful for therapeutic or prophylactic treatment of transient ischemic diseases such as coronary thrombosis, cerebral infarction, and the like, and essential hypertension. The above-identified compound (I) of the invention includes optically active isomers and racemate.

"Halogen" means fluoro, chloro, bromo, or iodo, with fluoro and chloro being preferred.

The compound of the invention represented by the formula (I) may be prepared according to the following reaction scheme.

Step 1

The starting compound (IV) is allowed to react with compound (V) to obtain compound (III). Solvents used for the reaction are alcohols such as methanol, ethanol, propanol, and isopropanol, nitriles such as acetonitrile and propionitrile, hydrocarbons such as benzene and toluene, ethers such as tetrahydrofuran and dioxane, ketones such as acetone and methyl ethyl ketone, amides such as N,N-dimethylformamide and N-methyl-2-pyridone, sulfides such as dimethylsulfoxide. Preferred solvents are alcohols, ethers, amides, and nitriles, with isopropanol and acetonitril being most preferred.

Bases used in the reaction may be selected from metal carbonates such as sodium carbonate and potassium carbonate, metal bicarbonates such as sodium bicarbonate and potassium bicarbonate, alkali metal hydride such as sodium hydride and lithium hydride, organic bases such as 1,5-diazabicyclo[4,3,0]non-5-ene and 1,8-diazabicyclo[5,4,0]undec-7-ene. Preferred bases are metal carbonates such as sodium carbonate and potassium carbonate, alkali metal hydride such as sodium hydride. The reaction temperature and reaction time will vary depending on particular base and solvent used. However, the reaction is generally carried out at 0-120 °C, preferably at 0-80 °C, for one hour-four days. When an inorganic base is employed in the reaction, addition of a catalyst amount of pyridines such as 4-dimethylaminopyridine or crown ethers such as 18-crown-6 may accelerate the reaction. The aimed product may be obtained by extracting it with an organic solvent, washing the extract with water, drying the extract over anhydrous magnesium sulfate, and evaporating the solvent. The product may be further purified by means of conventional procedures such as recrystallization, column chromatography, and the like, if desired.

Step 2

The compound (III) is allowed to react with compound (VI) to obtain compound (II). Solvents used for the reaction are alcohols such as methanol, ethanol, propanol, and isopropanol, nitriles such as acetonitrile and propionitrile, hydrocarbons such as benzene and toluene, ethers such as tetrahydrofuran and dioxane, ketones such as acetone and methyl ethyl ketone, amides such as N,N-dimethylformamide and N-methyl-2-pyridone, sulfides such as dimethylsulfoxide. Preferred solvents are alcohols such as methanol, ethanol, propanol and isopropanol, and nitriles such as acetonitrile and propionitrile, with ethanol, isopropanol and acetonitril being most preferred.

Bases used in the reaction may be selected from metal carbonates such as sodium carbonate and potassium carbonate, metal bicarbonates such as sodium bicarbonate and potassium bicarbonate, alkali
metal hydride such as sodium hydride and lithium hydride, organic bases such as 1,5-diazabicyclo[4,3,0]-non-5-ene and 1,8-diazabicyclo[5,4,0]undec-7-ene. Preferred bases are metal carbonates such as sodium carbonate and potassium carbonate, alkali metal hydride such as sodium hydride. The reaction temperature and reaction time will vary depending on particular base and solvent used. However, the reaction is generally carried out at 0-120 °C, preferably at 0-80 °C, for one hour-four days. When an inorganic base is employed in the reaction, addition of a catalytic amount of pyridines such as 4-dimethylaminopyridine or crown ethers such as 18-crown-6 may accelerate the reaction. The aimed product may be obtained by extracting it with an organic solvent, washing the extract with water, drying the extract over anhydrous magnesium sulfate, and evaporating the solvent. The product may be further purified by means of conventional procedures such as recrystallization, column chromatography, and the like, if desired.

Step 3

Compound (II) is reacted with compound (VII) to obtain compound (I). Any solvents can be used in the reaction as far as they don't interfere with the reaction. For example, hydrocarbons such as hexane, benzene, toluene, and cyclohexane, halogenated hydrocarbons such as dichloromethane, chloroform, and 1,2-dichloroethane, ethers, such as ether and tetrahydrofuran, esters such as ethyl acetate may be used. Preferred solvents are halogenated hydrocarbons, with dichloromethane being most preferred.

Bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminoypyridine, and N-methylmorpholine. A large excess of the base may be employed also as a solvent.

The reaction temperature may range from 0 °C to 80 °C, preferably from 0 °C to 50 °C. The reaction time varies depending on the reaction temperature, but the reaction will be completed within 1-24 hours, preferably 3-20 hours. The aimed product can be recovered by extracting the product with an organic solvent such as ethyl acetate, washing the extract with water, drying the washed extract over anhydrous magnesium sulfate, and evaporating the solvent from the dried extract. The product may further be purified by conventional procedures such as recrystallization, column chromatography, and the like.

The compound (I) of the invention and pharmaceutically acceptable salt thereof may be used as a therapeutical agent for treating circulatory diseases. The compound and its salt may be formulated into powders, granules, tablets, capsules, injections, and the like, with the aid of pharmaceutically acceptable carriers, excipients, and diluents, and they may be orally or parenterally administered to patients. The dosage varies depending on conditions of a particular patient and administration route. In general, however, the daily dosage will vary from 1 mg to 1000 mg, preferably from 1 mg to 100 mg, when orally administered, and it varies from 0.1 to 100 mg, preferably from 0.5 to 30 mg when intravenously administered. This dosage may be administered in one or two divided doses depending on the conditions of patients.

The following detailed examples are presented by way of illustration of certain specific embodiments of the invention.

Preparative Example

3-Acetoxy-5-{3-[4-(phenyl-1-piperaziny1)propyl]-2,3-dihydro-2-[4-methoxyphenyl]-8-chloro-1,5-benzothiazepin-4(5H)-one (I-I)

(1) 8.395 g (25.0 mmol) of 2-[4-methoxyphenyl]-3-hydroxy-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (IV-1), 4.723 g (30.0 mmol) of 1-bromo-3-chloropropane (V-1) and 4.146 g (30.0 mmol) of K$_2$CO$_3$ were dissolved in 168 ml of acetone, and the mixture was refluxed for 20 hours. The reaction mixture was evaporated under reduced pressure to give a residue, which was chromatographed on silica gel to give 10.96 g of cis-2-[4-(methoxyphenyl)-3-hydroxy-5-[3-chloropropyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (III-1) from dichloromethane effluent parts. The obtained compound was recrystallized from ethyl acetate to give 9.146 g as colorless prisms in 98.7% yield.

M.p.: 103-106 °C
IR $\nu_{\text{max}}$ (Nujol): 3452, 1651 cm$^{-1}$
NMR (CDCl$_3$): 2.19(2H,m), 2.84(0H), 3.69(3H,m), 4.63(1H,m), 3.82(3H,s), 4.31(1H,d), 4.93(1H,d), 6.90-7.75(7H,m).
(2) 412mg (1mmol) of the thus obtained compound (III-1) and 324mg (2mmol) of 4-phenylpiperazine (VI-1) were dissolved in 4ml of acetonitrile. To the mixture was added 166mg (1mmol) of potassium iodide as a catalyst, and the mixture was refluxed for 16 hours. The reaction mixture was evaporated under reduced pressure to give a residue, which was chromatographed on silica gel to give 440mg of cis-2-(4-methoxyphenyl)-3-hydroxy-5-[3-(4-phenylpiperazinyl)propyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4-(5H)-one (III-1) from ethyl acetate effluent parts. The compound (III-1) thus obtained was recrystallized from n-hexane to give 400mg as colorless prisms in 74.9% yield.
Mp.: 70-71 °C

**Elementary Analysis (%) for C$_{19}$H$_{15}$NO$_2$SCl$_2$:**

<table>
<thead>
<tr>
<th></th>
<th>Calcd.:</th>
<th>Found:</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>55.35;</td>
<td>55.31;</td>
</tr>
<tr>
<td>H</td>
<td>4.64;</td>
<td>4.70;</td>
</tr>
<tr>
<td>N</td>
<td>3.40</td>
<td>3.38</td>
</tr>
</tbody>
</table>

IR $\nu_{\text{max}}$ (Nujol): 3460, 1661, 1251, 1093 cm$^{-1}$
NMR (CDCl$_3$): 1.95(2H,m), 2.54(6H,m), 2.88(1H,d), 3.16(4H,m), 3.64(1H,m), 3.82(3H,s), 4.31(1H,d), 4.52(1H,d), 4.93(1H,d), 6.88(4H,m), 7.35(7H,m), 7.73(1H,d).
(3) To 5ml of acetic anhydride was added 800mg (1.5mmol) of the thus obtained compound (II-1) and the mixture was heated at 100 °C for 3 hours. The reaction mixture was evaporated under reduced pressure to give a residue, which was dissolved in 10ml of dichloromethane and neutralized with aqueous sodium bicarbonate. The dichloromethane layer was dried over sodium sulfate. The organic layer was chromatographed on silica gel to give 850mg of the objective compound (I-1) from ethyl acetate effluent parts. A hydrochloride of the thus obtained compound was recrystallized from acetone to give 600mg as colorless granular crystal in 61.3% yield.
Mp.: 143-146 °C

**Elementary Analysis (%) for C$_{29}$H$_{32}$Cl$_3$N$_2$O$_2$:**

<table>
<thead>
<tr>
<th></th>
<th>Calcd.:</th>
<th>Found:</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>64.74;</td>
<td>64.51;</td>
</tr>
<tr>
<td>H</td>
<td>6.00;</td>
<td>6.04;</td>
</tr>
<tr>
<td>N</td>
<td>7.81</td>
<td>7.77</td>
</tr>
</tbody>
</table>

IR $\nu_{\text{max}}$ (Nujol): 3420, 1750, 1684, 1250, 1180 cm$^{-1}$
NMR (CDCl$_3$): 1.91(3H,s), 2.4(2H,m), 3.34(4H,m), 3.5(6H,m), 3.83(3H,s), 4.13(2H,m), 5.05(1H,d), 5.12(1H,d), 6.93(2H,d), 7.4(9H,m), 7.76(1H,d).
It is to be noted that the above preparative example is not directed to making a compound according to this invention, but illustrates the procedure for making the following examples.

**Example**

Substantially in the same manner as in Example 1, the following compound 1 was prepared.
(1) 3-Acetoxy-5-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one (I-1)
Example 2

(2S-cis)-3-Acetoxy-5-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one (I-2)

10

\[
\begin{align*}
\text{Cl} & \quad \text{OCH}_3 \\
\text{N} & \quad \text{O} \\
\text{H} & \quad \text{OH} \\
\text{I V - 2} & 
\end{align*}
\]

(1) Substantially in the same manner as Example 1 (I), (2S-cis)-2-(4-methoxyphenyl)-3-hydroxy-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one as a starting material was treated.

(2) Substantially in the same manner as Example 1, Step 2 and Step 3, 4-(2-methoxyphenyl)piperazine was treated to give the objective compound (I-2) as colorless prisms in 97.0% yield. Mp.: 109-111 °C (recrystallization from ethyl acetate)

25

\[
\begin{align*}
\text{NH}_2 & \quad \text{N} \\
\text{OCH}_3 & \quad \text{OCH}_3 \\
\text{Cl} & \quad \text{OCH}_3 \\
\text{OH} & \\
\text{CH}_3 & \quad \text{N} \\
\text{I I I - 2} & 
\end{align*}
\]

\[
\begin{align*}
\text{Cl} & \quad \text{Br(CH}_2)_2\text{Cl} \\
\text{OH} & \quad \text{NH}_2 \\
\text{I V - 2} & 
\end{align*}
\]

second step

20

\[
\begin{align*}
\text{Cl} & \quad \text{OCH}_3 \\
\text{O} & \quad \text{OH} \\
\text{CH}_3 & \quad \text{N} \\
\text{I I I - 2} & 
\end{align*}
\]

\[
\begin{align*}
\text{Ac}_2\text{O} & \\
\text{I - 2} & 
\end{align*}
\]

third step

25

(1) Substantially in the same manner as Example 1 (1), (2S-cis)-2-(4-methoxyphenyl)-3-hydroxy-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one was treated to give the objective compound (I-2) as colorless prisms in 97.0% yield. Mp.: 109-111 °C (recrystallization from ethyl acetate)

35

\[
\begin{array}{|l|l|l|l|}
\hline
\text{Elementary Analysis(%) for } & \text{C}_{32}\text{H}_{33}\text{ClN}_{3}\text{O}_{3}\text{S} & \\
\text{Calcld.:} & \text{C}, 62.99; & \text{H}, 5.95; & \text{N}, 6.89; \\
\text{Found:} & \text{C}, 63.09; & \text{H}, 6.00; & \text{N}, 6.77; \\
\hline
\end{array}
\]

40

IR ν max (Nujol): 1746, 1678 cm⁻¹
NMR (CDCl₃): 2.19(2H, m), 1.91(3H, s), 2.77(10H, m), 3.63(1H, m), 4.47(1H, m), 3.83(3H, s), 3.85(3H, s), 5.03(1H, d), 5.15(1H, d), 7.26(11H, m)
Specific rotation: [α]D +109.3±1.5 (25 °C, c = 1.007, MeOH)

45

Examples 3-6

Substantially in the same manner as in Example 2, the following compounds I-3 - l-14 were prepared.

(3) (2S-cis)-3-Acetoxy-5-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one hydrochloride (I-3)

(4) (2S-cis)-3-Acetoxy-5-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one phosphate (I-4)

(5) (2S-cis)-3-Acetoxy-5-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one citrate (I-5)

(6) (2S-cis)-3-Acetoxy-5-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one fumarate (I-6)

(7) (2S-cis)-3-Acetoxy-5-[3-(4-(4-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one (I-7)

(8) (2S-cis)-3-Acetoxy-5-[3-(4-(4-methoxyphenyl)-1-piperazinyl)butyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one (I-8)
(9) (2S-cis)-3-Acetoxy-5-[5-(4-(2-methoxyphenyl)-1-piperazinyl)pentyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one (I-9)
(10) (2S-cis)-3-Acetoxy-5-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-methoxy-1,5-benzothiazepin-4(5H)-one (I-10)
(11) (2S-cis)-3-Acetoxy-5-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-methyl-1,5-benzothiazepin-4(5H)-one (I-11)
(12) (2S-cis)-3-Hydroxy-5-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one (I-12)
(13) (2R-cis)-3-Acetoxy-5-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one (I-13)
(14) (2S-trans)-3-Acetoxy-5-[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]-2,3-dihydro-2-(4-methoxyphenyl)-8-chloro-1,5-benzothiazepin-4(5H)-one (I-14)

The chemical structures and yields of the above compounds (except for compound I-8) are listed in Table 1, and the detailed reaction conditions are summarized in Table 2. In addition, Table 3 shows physico-chemical properties of the aimed product and the solvents used for their recrystallization.

<table>
<thead>
<tr>
<th>Example No.</th>
<th>X: =N-A-R¹</th>
<th>z</th>
<th>n</th>
<th>Y</th>
<th>yield(%)</th>
<th>yield(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>g</td>
<td>3</td>
<td>Cl</td>
<td>99.3 f</td>
<td>84.5</td>
</tr>
<tr>
<td>1</td>
<td>A; single bond</td>
<td>R¹: o-methoxy-phenyl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>A; single bond</td>
<td>R¹: o-methoxy-phenyl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>A; single bond</td>
<td>R¹: o-methoxy-phenyl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>A; single bond</td>
<td>R¹: o-methoxy-phenyl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>A; single bond</td>
<td>R¹: o-methoxy-phenyl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>A; single bond</td>
<td>R¹: o-methoxy-phenyl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>A; single bond</td>
<td>R¹: p-methoxy-phenyl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>A; single bond</td>
<td>R¹: o-methoxy-phenyl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>A; single bond</td>
<td>R¹: o-methoxy-phenyl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1

8
1) A: single bond  
R': o-methoxy-phenyl  
g 3 CH₂O⁻  88.0  a  85.0

1) A: single bond  
R': o-methoxy-phenyl  
g 3 CH₃⁻  93.0  a  94.0

1) A: single bond  
R': o-methoxy-phenyl  
h 3 Cl  ---  85.5  a

1) A: single bond  
R': o-methoxy-phenyl  
g 3 Cl  69.8  84.7

1) A: single bond  
R': o-methoxy-phenyl  
g 3 Cl  47.0  c  not isolated

---

a: hydrochloride  
b: phosphate  
c: citrate  
d: fumarate  
e: oxalate  
g: acetyl  
h: hydrogen

---

Table 2
(Step 1)

<table>
<thead>
<tr>
<th>Example No.</th>
<th>Starting Compound mg(mmol) Comp.(III)</th>
<th>Starting Compound mg(mmol) Comp.(IV)</th>
<th>Solvent (ml)</th>
<th>Potassium Iodide (mg(mmol))</th>
<th>Reaction Temperature (°C)</th>
<th>Reaction Time (hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>412(1)</td>
<td>384(2)</td>
<td>a 4</td>
<td>166(1)</td>
<td>82</td>
<td>16</td>
</tr>
</tbody>
</table>
Table 2 (continued)

<table>
<thead>
<tr>
<th>Example No.</th>
<th>Starting Compound mg(mmol)</th>
<th>Solvent (ml)</th>
<th>Potassium Iodide mg(mmol)</th>
<th>Reaction Temperature (°C)</th>
<th>Reaction Time (hour)</th>
<th>Potassium Carbonate mg(mmol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>412(1)</td>
<td>384(2)</td>
<td>a 4</td>
<td>166(1)</td>
<td>82</td>
<td>16</td>
</tr>
<tr>
<td>4</td>
<td>412(1)</td>
<td>384(2)</td>
<td>a 4</td>
<td>166(1)</td>
<td>82</td>
<td>16</td>
</tr>
<tr>
<td>5</td>
<td>412(1)</td>
<td>384(2)</td>
<td>a 4</td>
<td>166(1)</td>
<td>82</td>
<td>16</td>
</tr>
<tr>
<td>6</td>
<td>412(1)</td>
<td>384(2)</td>
<td>a 4</td>
<td>166(1)</td>
<td>82</td>
<td>16</td>
</tr>
<tr>
<td>7</td>
<td>1030(2.5)</td>
<td>793(3)b</td>
<td>d 5</td>
<td>625(3.8)</td>
<td>100</td>
<td>1.5</td>
</tr>
<tr>
<td>8</td>
<td>613(1.44)</td>
<td>395(1.73)</td>
<td>d 6</td>
<td>239(1.4)</td>
<td>100</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>642(1.46)</td>
<td>400(1.75)</td>
<td>d 6</td>
<td>242(1.46)</td>
<td>100</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>490(1.2)</td>
<td>460(2.4)</td>
<td>d 10</td>
<td>400(2.4)</td>
<td>100</td>
<td>2.5</td>
</tr>
<tr>
<td>11</td>
<td>340(0.87)</td>
<td>335(1.74)</td>
<td>d 7</td>
<td>289(1.74)</td>
<td>100</td>
<td>2.5</td>
</tr>
<tr>
<td>12</td>
<td>412(1)</td>
<td>384(2)</td>
<td>a 4</td>
<td>166(1)</td>
<td>82</td>
<td>16</td>
</tr>
<tr>
<td>13</td>
<td>1120(2.7)</td>
<td>652(2.9)</td>
<td>d 5.6</td>
<td>451(2.7)</td>
<td>100</td>
<td>2</td>
</tr>
<tr>
<td>14</td>
<td>1120(2.7)</td>
<td>652(2.9)</td>
<td>d 5.6</td>
<td>451(2.7)</td>
<td>100</td>
<td>2</td>
</tr>
</tbody>
</table>

a: acetonitrile  
b: hydrochloride  
d: dimethylformamide

Table 2 (continued)

Step 3

<table>
<thead>
<tr>
<th>Example No.</th>
<th>Starting Compound mg(mmol)</th>
<th>Ac₂O (ml)</th>
<th>Reaction Temperature (°C)</th>
<th>Reaction Time (hour)</th>
<th>Base mg (mmol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>400(0.71)</td>
<td>10</td>
<td>100</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>400(0.71)</td>
<td>10</td>
<td>100</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>400(0.71)</td>
<td>10</td>
<td>100</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>400(0.71)</td>
<td>10</td>
<td>100</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>400(0.71)</td>
<td>10</td>
<td>100</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>1640(2.66)</td>
<td>5</td>
<td>30</td>
<td>15</td>
<td>m 20(0.17)</td>
</tr>
<tr>
<td>Exam. No.</td>
<td>Appearance</td>
<td>Recrystallization</td>
<td>Solvent</td>
<td>MP(°C)</td>
<td>Specific Rotation <em>d</em>&lt;sub&gt;25&lt;/sub&gt;</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>-------------------</td>
<td>---------</td>
<td>--------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>1-I b</td>
<td>CG</td>
<td>acetone</td>
<td>183-185</td>
<td>1749,1686</td>
<td></td>
</tr>
<tr>
<td>1-II</td>
<td>CP</td>
<td>hexane</td>
<td>75-76</td>
<td>1662</td>
<td></td>
</tr>
<tr>
<td>3-I a</td>
<td>CP</td>
<td>acetone</td>
<td>147-150</td>
<td>67.9±1.1(c=1.012)</td>
<td>3374,2282, 1745,1677</td>
</tr>
<tr>
<td>3-II</td>
<td>oil</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>4-I c</td>
<td>CP</td>
<td>methanol</td>
<td>140-143</td>
<td>69.9±1.1(c=1.005)</td>
<td>2350,1742, 1680</td>
</tr>
<tr>
<td>5-I d</td>
<td>CP</td>
<td>methanol</td>
<td>187-189</td>
<td>65.0±1.0(c=1.007)</td>
<td>3430,2620, 1737,1674</td>
</tr>
<tr>
<td>6-I e</td>
<td>CP</td>
<td>ethanol</td>
<td>115-117</td>
<td>69.6±1.1(c=1.003)</td>
<td>3276,2506, 1741,1672</td>
</tr>
</tbody>
</table>

m: dimethylaminopyridine  
p: pyridine
7-1 d CP ethanol 197-198 + 58.8±1.0(c=1.004) -
7-II oil - - - -
8-I CP hexane 139-140 + 90.9±1.3(c=1.013) 1743,1676
8-II oil - - - -
9-I a CA - - + 76.2±1.2(c=1.008) *3486,2390,
1739,1676
9-II CA - - - -
10-I a CA - - + 70.1±1.1(c=1.003) -
10-II oil - - - -
11-I a CA - - + 80.5±1.2(c=1.005) -
11-II oil - - - -
12-II a CP acetone 135-137 + 83.8±1.2(c=1.007) 3380,2360,
1660
13-I CP hexane 109-111 -110.1±1.5(c=1.018) 1746,1678
13-II CN hexane 175-178 - -
14-1 d CP methanol 191-192 +275.8±3.1(c=1.018) 3446,2542,
1736,1640
14-II oil - - - -

a: hydrochloride   b: oxalate   c: phosphate

d: citrate         e: fumarate
*: in chloroform

CA: colorless amorphous   CN: colorless needles

Following pharmacological experiments were conducted on the compounds (I) of the invention.

Experiment 1

Calcium Channel Antagonism and α-Blocking Action (Relaxing Action on Extracted Blood Vessel)

Male rabbits weighing 2-3kg (Rabiton, Japanese albino species) were anesthetized through intravenous administration of pentobarbital (50mg/kg), and sacrificed by bloodletting through dissection of axillary artery. Femoral artery was extracted, connective tissue surrounding the artery was removed, and helical specimen was prepared. The specimen was suspended in an organ bath (20cc) filled with 37°C Krebs-Henseleit nutritious solution and bubbled with a 95% O₂ + 5% CO₂ mixed gas. 1.5g of resting tension was loaded on femoral artery. Isometric change of the tension of the specimen was recorded on a thermal recorder (Nippon Koden WT-685G) via F-D pickup Nippon Koden (TB-611T) and Preamp (Nippon Koden). Ca-antagonism of a test compound was evaluated by observing relaxing action due to accumulative addition of the compound on the contracture caused by the application of 50 mM KC1. α-Blocking action was similarly evaluated by observing such relaxing action on the contracture caused by the application of 1μM norepinephrine (NE). Maximum relaxing ability possessed by the blood vessel was defined as the same as relaxing response of the vessel observed when 0.1mM of papaverine was applied. The concentration of a given compound, which is necessary for giving 50% of the maximum relaxing (IC₅₀), was determined using the above system. The results are shown in Table 4.
Table 4

<table>
<thead>
<tr>
<th>Compound No.</th>
<th>Relaxing action on Blood Vessel IC\textsubscript{50}(\times 0.1\mu M)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>50mM-KCl</td>
</tr>
<tr>
<td>I-1</td>
<td>2.8</td>
</tr>
<tr>
<td>I-3</td>
<td>2.5</td>
</tr>
<tr>
<td>I-10</td>
<td>1.2</td>
</tr>
<tr>
<td>I-11</td>
<td>1.4</td>
</tr>
<tr>
<td>Diltiazem</td>
<td>4.2</td>
</tr>
</tbody>
</table>

Experiment 2

Anti-hypoxia action on cultured cardiac cells

Anti-hypoxia action of the compounds of the present invention were investigated through studying their action in connection with the protection of cardiomuscular cells.

Primary culture of cardiac cells was prepared from newborn Crj-SD rats (2-3 day old) and used in the experiment. The primary culture was prepared according to the method described by Jones R. L. et al., Am. J. Pathol., 135, 541-556, 1989. Thus, cardiac cells were isolated from ventricle muscle using collagenase and pancreatin, and then the cardiac cells were separated and purified from cell debris, erythrocytes, and fibroblasts by means of Percoll density-gradient centrifugation. The cells were spread on a culture plate at a ratio of 2-3 \times 10^6 cells/3.5cm plate, and the cells were cultured for two days in Dulbecco’s Modified Eagle’s Medium (DMFM) containing 10% Fetal Bovine Serum (FBS) in an incubator (5% CO\textsubscript{2}/95% Air) kept at 37°C. After sufficient growth of the cardiac cells, the culture medium was changed to DMEM free from FBS, and the culture was continued additional one day. The cells thus obtained were used in the experiment.

Hypoxia was generated using Gas Pak™ Anaerobic Chamber (BBL) which produces hypoxia by capturing residual O\textsubscript{2} and changing it into H\textsubscript{2}O by the action of a H\textsubscript{2}/CO\textsubscript{2} generating bag and catalyst. The cardiac cell plate, wherein the culture medium had been changed to DMEM which is free from FBS and glucose, was set in the chamber, and the chamber was placed in an incubator. Anti-hypoxia activity of test compounds was determined by measuring inhibition rate of leakage of creatine phosphokinase activity into the culture medium.

The compounds tested were all dissolved in DMSO using HCO-50 as a solubilizing agent (DMSO:HCO-50 = 9:1), and directly charged on to the culture plate. The final concentrations of DMSO and HCO-50 in the culture medium were adjusted to 0.09% and 0.01% respectively. CPK activity was measured by colorimetry (Wako Kit) modified from Oliver method. The test results are summarized in Table 5.

Table 5

<table>
<thead>
<tr>
<th>Compound No.</th>
<th>Anti-hypoxia Activity(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1\mu M</td>
</tr>
<tr>
<td>I-1</td>
<td>17</td>
</tr>
<tr>
<td>I-3</td>
<td>23.7</td>
</tr>
<tr>
<td>I-7</td>
<td>30</td>
</tr>
<tr>
<td>I-8</td>
<td>36.9</td>
</tr>
<tr>
<td>I-9</td>
<td>-</td>
</tr>
<tr>
<td>Diltiazem</td>
<td>10</td>
</tr>
</tbody>
</table>

The numerical values in the table show cardiac cells-protecting activity of test compounds in terms of the rate (%) of inhibition on CPK leakage determined in connection with the test compounds when the amount of the CPK leakage for negative control (no addition of the test compounds) was defined as 100%. Table 5 clearly shows that the compounds of the present invention display higher protecting activity than
the positive control (diltiazem).

Experiment 3

Action of the compounds of the invention on blood pressure and heart rate of not-anesthetized spontaneous hypertensive rats (SHR)

Male Japanese Charles-River SHR (13-17 week old) were used in the experiment (S. Matsuda, J. Pharmacol. Method, 17 361, 1987). Systolic blood pressure (SBP) and heart rate of the animals were measured non-invasively (indirectly) using hemodynamometer for caudal artery pressure (6 channel type) before the administration of test compounds, at 2 and 4 hours after administration. Test compounds were dissolved in DMSO (100%) and orally administered. Decreased values in SBP and heart rate determined 2 and 4 hours after administration when compared with those determined before administration are shown in percentage (%) in the following table.

<table>
<thead>
<tr>
<th>Compound No. (30mg/kg PO)</th>
<th>Antihypertensive action (%)</th>
<th>Decrease of heart rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-1</td>
<td>15</td>
<td>3.2</td>
</tr>
<tr>
<td>I-3</td>
<td>18</td>
<td>7.0</td>
</tr>
<tr>
<td>Diltiazem&lt;sup&gt;a&lt;/sup&gt;</td>
<td>11</td>
<td>15</td>
</tr>
</tbody>
</table>

<sup>a</sup>: 60mg/kg PO

Experiment 4

Anti-necrosis activity

Male Slc Wistar rats weighing 200-250g were anesthetized with urethane (1g/kg), and ramus descendens of the left coronaria was ligated for 20 minutes and then reperfused according to the method described by Hock et al (Hock, C. E., Ribeiro, L. G., Tand Lefer, A. M., Am. Heart J., 109 222, 1985). Compounds to be tested were dissolved in physiological saline, or first dissolved in a DMSO/HCO-50 (9:1) mixture and then diluted with physiological saline or 0.25M aqueous sucrose solution, and infused into the right cervical vein at a ratio of 0.15ml/kg/minute for ten minutes before the ligation. For three hours after the reperfusion, the rats were subjected to heat insulation on a warming mat. After 120 minutes, the hearts were extracted, and the free walls of the left ventricles were frozen and stored until determination of CPK activity.

CPK activity was determined according to the method of Bernauer, W. (Arch. int. Pharmacodynam., 231 90, 1978) after minor modification. Thus, the extracted tissue was homogenized in 10 volumes of 0.1M Tris/HCl (pH7.5) containing 1mM mercaptoethanol and centrifuged at 20,000g for 20 minutes. The supernatant was used for determination of CPK activity, which was conducted using a commercially available kit (CPK-Test, Wako). CPK was determined using serum CPK as a standard and expressed with "U/mg protein".

The inhibition of cardiac muscle damage due to ischemia, which should be obtained when a test compound is administered, was compared with the inhibition obtained when an active control, diltiazem, was administered. The degree of the inhibition was measured in terms of the CPK activity retained in the left ventricle. The test results are shown in Table 7, wherein percentage of the retention (%) at each dose was calculated based on the following equation.

Retention (%) = [(Retained CPK activity when a test compound was administered)-(Retained CPK activity when only a medium was administered)]/[(CPK activity possessed by intact animals)-(Retained CPK activity when only a medium was administered)]
Table 7

<table>
<thead>
<tr>
<th>Compound No.</th>
<th>Retention (%) (anti-necrosis activity) mg/kg (iv)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.1</td>
</tr>
<tr>
<td>I-1</td>
<td>30</td>
</tr>
<tr>
<td>I-3</td>
<td></td>
</tr>
<tr>
<td>I-10</td>
<td>42</td>
</tr>
<tr>
<td>I-11</td>
<td></td>
</tr>
<tr>
<td>Diltiazem</td>
<td></td>
</tr>
</tbody>
</table>

Claims

1. A compound of the formula:

   \[
   \begin{align*}
   Y & \quad \text{OCH}_3 \\
   \text{OZ} & \quad (\text{I}) \\
   (\text{CH}_2)_n & \quad \text{N} \\
   \text{X} & \\
   \end{align*}
   \]

   wherein \( X \) is \( = \text{N-R}^1 \); \( R^1 \) is methoxyphenyl; \( Y \) is halogen, methyl or methoxy; \( Z \) is hydrogen or acetyl; \( n \) is an integer of from 3 to 6, and a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1, wherein \( n \) is 3.

3. A compound of the formula:

   \[
   \begin{align*}
   \text{OMe} & \\
   \text{OAc} & \quad \text{O} \\
   (\text{CH}_2)_3 & \quad \text{N} \\
   \text{OMe} & \\
   \end{align*}
   \]

4. A compound as claimed in claim 3, which is an \((+)-\)isomer

5. A pharmaceutical composition which comprises an effective amount of a compound as claimed in any preceding claim in association with a pharmaceutically acceptable carrier, excipient or diluent.
6. The use of a compound as claimed in any one of claims 1 to 4 for the preparation of a pharmaceutical formulation for the treatment of cardiac disease.

7. The use of a compound as claimed in any one of claims 1 to 4 for the preparation of a pharmaceutical formulation for the treatment of hypertension.

**Patentansprüche**

1. Verbindung der Formel

\[
\begin{align*}
&\text{Y} \\
&\text{OCH}_3 \\
&\text{N} \\
&(\text{CH}_3)_n \\
&\text{N} \\
&\text{X}
\end{align*}
\]

in der X die Gruppe \( =\text{N-R}^1 \) ist, \( \text{R}^1 \) eine Methoxyphenylgruppe ist, \( \text{Y} \) ein Halogenatom, eine Methyl- oder Methoxygruppe ist; \( \text{Z} \) ein Wasserstoffatom oder eine Acetylgruppe ist, \( n \) eine ganze Zahl von 3 bis 6 ist, und ein pharmaceutisch verträgliches Salz davon.

2. Verbindung nach Anspruch 1, in der \( n \) der Wert 3 ist.

3. Verbindung der Formel

\[
\begin{align*}
&\text{Cl} \\
&\text{S} \\
&\text{OAc} \\
&(\text{CH}_2)_3\text{N} \\
&\text{OMe}
\end{align*}
\]

4. Verbindung nach Anspruch 3, die ein (\( + \))-Isomer ist.

5. Arzneimittel, das eine wirksame Menge einer in einem vorhergehenden Anspruch beanspruchten Verbindung zusammen mit einem pharmaceutisch verträglichen Trägerstoff, Exzipienten oder Verdünnungsmittel enthält.


Reondications

1. Composé répondant à la formule :

\[ \text{I} \]

\[ \text{II} \]

dans laquelle \( X = \text{N-R}^1 \); \( R^1 \) est un groupe méthoxyphénylé; \( Y \) est un atome d'halogène, un groupe méthyle ou méthoxy; \( Z \) est un atome d'hydrogène ou un groupe acétylé; \( n \) est un entier de 3 à 6, et un de ses sels pharmaceutiquement acceptables.

2. Composé selon la revendication 1, dans lequel \( n \) est 3.

3. Composé répondant à la formule :

\[ \text{III} \]

4. Composé selon la revendication 3, qui est un isomère (+).

5. Composition pharmaceutique qui comprend une quantité efficace d'un composé selon l'une quelconque des revendications précédentes associé à un support, excipient ou diluant pharmaceutiquement acceptable.

6. Utilisation d'un composé selon l'une quelconque des revendications 1 à 4 pour la préparation d'une formule pharmaceutique pour le traitement des maladies cardiaques.

7. Utilisation d'un composé selon l'une quelconque des revendications 1 à 4 pour la préparation d'une formule pharmaceutique pour le traitement de l'hypertension.